Sinopharm's COVID-19 vaccines show efficacy of over 72%

China's Sinopharm has released its report on phase III clinical trials on inactivated COVID-19 vaccines. 

The two vaccines, developed by its Wuhan and Beijing institutes, have an efficacy of 72.8% and 78.1%, respectively, according to a study published in The Journal of the American Medical Association (JAMA) on Wednesday.